nemvaleukin alfa
nemvaleukin alfa: sourced relationships with 1 company · 2 clinical trials tracked.
nemvaleukin alfa evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could nemvaleukin alfa → MURA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Mural Oncology plc (MURA) Cutaneous Melanoma | Phase 3 |
Clinical Trial Registry Records (2)
A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
Primary endpoint: Centrally-assessed overall response rate (ORR) (Cohort 1 and 2)
A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1
Primary endpoint: Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)
Frequently asked questions
Which companies have sourced relationships with nemvaleukin alfa?
nemvaleukin alfa has dated SEC/FDA relationship records for Mural Oncology plc.
How many clinical trials involve nemvaleukin alfa?
BioSniper tracks 2 clinical trials involving nemvaleukin alfa.